MacroGenics, Inc. (MGNX) NASDAQ
4.20
+0.15(+3.70%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
4.20
+0.15(+3.70%)
Currency In USD
| Previous Close | 4.05 |
| Open | 4.04 |
| Day High | 4.3 |
| Day Low | 4 |
| 52-Week High | 4.64 |
| 52-Week Low | 1.19 |
| Volume | 626,895 |
| Average Volume | 1.3M |
| Market Cap | 266.97M |
| PE | -3.78 |
| EPS | -1.11 |
| Moving Average 50 Days | 3.48 |
| Moving Average 200 Days | 2.19 |
| Change | 0.15 |
MacroGenics Announces Pausing of Enrollment of New Study Participants in LINNET Trial
GlobeNewswire Inc.
Feb 23, 2026 11:14 PM GMT
FDA has placed partial clinical hold on LINNET study of lorigerlimab in gynecologic cancerROCKVILLE, MD, Feb. 23, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovativ
MacroGenics to Participate in the 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 9:05 PM GMT
ROCKVILLE, MD, Nov. 25, 2025 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and
MacroGenics Reports Third Quarter 2025 Financial Results and Provides Update on Corporate Progress
GlobeNewswire Inc.
Nov 12, 2025 9:01 PM GMT
Achieved additional $75 million in partnering proceeds from Sanofi and GileadGranted license to additional preclinical program to Gilead that leverages MacroGenics’ novel T-cell engager platformRealigned pipeline priorities by ending development of l